New Delhi, October 26, 2026: In India, breast cancer is the the most common cancer among women in India, as per IARC/GLOBOCAN 2024, breast cancer in India accounted for an estimated 237,231 new cases and 96,100 deaths in 2024. The disease is considered among the most complex and heterogeneous, making it one of the most significant cancer challenges in India and worldwide.
Over the past few years, advances in screening, diagnosis, and treatment of the highly complex and heterogeneous disease have improved outcomes for many patients. However, the increasing number of breast cancer patients in India and the the biological complexity of the disease are making it more essential for researchers, genomics laboratories and scientists to precisely understand the complexities in order to advance cancer research and develop future precision-medicine approaches.
The contribution of DSS Takara Bio India’s advanced molecular biology and next-generation sequencing technologies, therefore, remains significant in the evolution of the breast cancer landscape in India. The company’s research-use molecular biology, genomics and sequencing-workflow technologies are increasingly supporting researchers, genomics laboratories and scientists in their study of breast-cancer biology, biomarkers, immune responses, tumour heterogeneity and mechanisms of treatment response or resistance.
DSS Takara Bio’s technologies range across RNA sequencing, immune-repertoire profiling, ctDNA and low-input DNA workflows, methylation research, single-cell genomics, spatial omics and PCR/qPCR-based validation. They support researchers and laboratories across this evolving research landscape with molecular biology, genomics, single-cell and spatial research technologies designed to enable deeper investigation of disease biology.
“Breast-cancer research is becoming increasingly multidimensional. No single technology can capture the full complexity of breast cancer. Together, DSS Takara Bio’s range of technologies help researchers build a more connected picture of breast-cancer biology. This macro-perspective, in turn, enables them to create new opportunities to discover biomarkers, identify potential therapeutic targets, understand mechanisms of disease progression, and advance more personalised approaches to cancer research and, ultimately, patient care,” said Harkaran Dhingra, CEO, DSS Takara Bio.
DSS Takara Bio’s range:
-Immune profiling technologies provide insight into how T-cell populations and immune responses may change in association with disease.
-Liquid biopsy enables researchers to investigate tumor evolution through circulating DNA.
-Long-read transcriptomics reveals full-length transcript structures, isoform diversity, and fusion events.
-RNA-focused approaches provide insight into regulatory mechanisms that can influence tumour progression and metastasis.
-Epigenetic analysis adds another layer of biological context, while single-cell approaches can reveal genomic differences hidden within individual tumor or circulating tumour cells.
“Researchers across the world are still uncovering just how biologically complex breast cancer can be. Going forward, sustained scientific research, access to quality healthcare and collaboration across the scientific and healthcare ecosystem will become critical to advancing our understanding of breast cancer,” Harkaran Dhingra, CEO, DSS Takara Bio added.
